Company intelligence / Profile preview
Graphium Biosciences
Cleveland, Ohio, United Statesgraphiumbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Graphium’s lead candidate, VBX‑100—a glycosylated THC molecule—has shown positive efficacy in two industry-standard colitis models in animals. It has received FDA Orphan Drug Designation for pediatric ulcerative colitis. Multiple compounds have been tested in mouse, rat, and monkey studies. No clinical trial results are available yet.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Small moleculeGlycosylated cannabinoid
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Graphium Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Graphium Biosciences.